Discovery of necrosis avidity of rhein and its applications in necrosis imaging

References

• Zhang D, Gao M, Jin Q, et al. Updated developments on molecular imaging and therapeutic strategies directed against necrosis. Acta Pharm Sin B. 2019;9(3):455–468.
   PubMed Web of Science ®Google Scholar
• Cona M, Oyen R, Ni Y. Necrosis avidity of organic compounds: a natural phenomenon with exploitable theragnostic potentials. CMC. 2015;22(15):1829–1849.
   PubMed Web of Science ®Google Scholar
• Bonte FJ, Parkey RW, Graham KD, et al. A new method for radionuclide imaging of myocardial infarcts. Radiology. 1974;110(2):473–474.
   PubMed Web of Science ®Google Scholar
• Ni Y. Metalloporphyrins and functional analogues as MRI contrast agents. CMIR. 2008;4(2):96–112.
   Web of Science ®Google Scholar
• Ni Y, Bormans G, Chen F, et al. Necrosis avid contrast agents: functional similarity versus structural diversity. Invest Radiol. 2005;40(8):526–535.
   PubMed Web of Science ®Google Scholar
• Jiang B, Wang J, Ni Y, et al. Necrosis avidity: a newly discovered feature of hypericin and its preclinical applications in necrosis imaging. Theranostics. 2013;3(9):667–676.
   PubMed Web of Science ®Google Scholar
• Li J, Oyen R, Verbruggen A, et al. Small molecule sequential dual-targeting theragnostic strategy (SMSDTTS): from preclinical experiments towards possible clinical anticancer applications. J Cancer. 2013;4(2):133–145.
   PubMed Web of Science ®Google Scholar
• Cona MM, de Witte P, Verbruggen A, et al. An overview of translational (radio) pharmaceutical research related to certain oncological and non-oncological applications. WJM. 2013;3(4):45–64.
   Google Scholar
• De Saint-Hubert M, Bauwens M, Deckers N, et al. In vivo molecular imaging of apoptosisand necrosis in atherosclerotic plaquesusing microSPECT-CT and microPET-CT imaging. Mol Imaging Biol. 2014;16(2):246–254.
   PubMed Web of Science ®Google Scholar
• Fang C, Wang K, Zeng C, et al. Illuminating necrosis: From mechanistic exploration to preclinical application using fluorescence molecular imaging with indocyanine green. Sci Rep. 2016;6(1):21013.
   PubMed Web of Science ®Google Scholar
• Xie B, Stammes MA, van Driel P, et al. Necrosis avid near infrared fluorescent cyanines for imaging cell death and their use to monitor therapeutic efficacy in mouse tumor models. Oncotarget. 2015;6(36):39036–39049.
   PubMedGoogle Scholar
• Stammes MA, Maeda A, Bu J, et al. The necrosis-avid small molecule HQ4-DTPA as a multimodal imaging agent for monitoring radiation therapy-induced tumor cell death. Front Oncol. 2016;6:221.
   PubMed Web of Science ®Google Scholar
• Stammes MA, Knol-Blankevoort VT, Cruz LJ, et al. Pre-clinical evaluation of a cyanine-based SPECT probe for multimodal tumor necrosis imaging. Mol Imaging Biol. 2016;18(6):905–915.
   PubMed Web of Science ®Google Scholar
• Zhu M, Lin XA, Zha XM, et al. Evaluation of the therapeutic efficacy of sequential therapy involving percutaneous microwave ablation in combination with 131I-hypericin using the VX2 rabbit breast solid tumor mode. PLoS One. 2015;10(3):e0120303.
   PubMed Web of Science ®Google Scholar
• Jendželovská Z, Jendželovský R, Kuchárová B, et al. Hypericin in the light and in the dark: two sides of the same coin. Front Plant Sci. 2016;7:560.
   PubMed Web of Science ®Google Scholar
• Rybczynska AA, Boersma HH, de Jong S, et al. Avenues to molecular imaging of dying cells: Focus on cancer. Med Res Rev. 2018;38(6):1713–1768.
   PubMed Web of Science ®Google Scholar
• Li Y, Wang S, Zhao Y, et al. A model in vitro study using hypericin:tumor-versus necrosis-targeting property and possible mechanisms. Biology. 2020;9(1):13.
   Web of Science ®Google Scholar
• Zhou YX, Xia W, Yue W, et al. Rhein: a review of pharmacological activities. Evid Based Complement Alternat Med. 2015;2015:1–10.
   Web of Science ®Google Scholar
• Sun H, Luo G, Chen D, et al. A comprehensive and system review for the pharmacological mechanism of action of rhein, an active anthraquinone ingredient. Front Pharmacol. 2016;7:247.
   PubMed Web of Science ®Google Scholar
• Wu C, Cao H, Zhou H, et al. Research progress on the antitumor effects of rhein: literature review. Anticancer Agents Med Chem. 2017;17(12):1624–1632.
   PubMed Web of Science ®Google Scholar
• Li J, Sun Z, Zhang J, et al. A dual-targeting anticancer approach: soil and seed principle. Radiology. 2011;260(3):799–807.
   PubMed Web of Science ®Google Scholar
• Li J, Cona MM, Chen F, et al. Exploring theranostic potentials of radioiodinated hypericin in rodent necrosis models. Theranostics. 2012;2(10):1010–1019.
   PubMed Web of Science ®Google Scholar
• Li J, Cona MM, Chen F, et al. Sequential systemic administrations of combretastatin A4 Phosphate and radioiodinated hypericin exert synergistic targeted theranostic effects with prolonged survival on SCID mice carrying bifocal tumor xenografts. Theranostics. 2013;3(2):127–137.
   PubMed Web of Science ®Google Scholar
• Kong M, Zhang J, Jiang C, et al. Necrosis affinity evaluation of 131I-hypericin in a rat model of induced necrosis. J Drug Target. 2013;21(6):604–610.
   PubMed Web of Science ®Google Scholar
• Ji Y, Zhan Y, Jiang C, et al. Improvement of solubility and targetability of radioiodinated hypericin by using sodium cholate based solvent in rat models of necrosis. J Drug Target. 2014;22(4):304–312.
   PubMed Web of Science ®Google Scholar
• Cona MM, Feng Y, Verbruggen A, et al. Improved clearance of radioiodinated hypericin as a targeted anticancer agent by using a duodenal drainage catheter in rats. Exp Biol Med (Maywood). 2013;238(12):1437–1449.
   PubMed Web of Science ®Google Scholar
• Jiang C, Li Y, Jiang X, et al. Hypericin as a marker for determination of myocardial viability in a rat model of myocardial infarction. Photochem Photobiol. 2014;90(4):n/a–872.
   Web of Science ®Google Scholar
• Qi X, Shao H, Zhang J, et al. Radiopharmaceutical study on Iodine-131-labelled hypericin in a canine model of hepatic RFA-induced coagulative necrosis. Radiol Med. 2015;120(2):213–221.
   PubMed Web of Science ®Google Scholar
• Cona MM, Alpizar YA, Li J, et al. Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation. Pharm Res. 2014;31(2):278–290.
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang C, Li Y, et al. Evaluation of hypericin: effect of aggregation on targeting biodistribution. J Pharm Sci. 2015;104(1):215–222.
   PubMed Web of Science ®Google Scholar
• Ji Y, Jiang C, Zhang X, et al. Necrosis targeted combinational theragnostic approach to treat cancer. Oncotarget. 2014;5(10):2934–2946.
   PubMedGoogle Scholar
• Cona MM, Feng Y, Zhang J, et al. Sodium cholate, a solubilizing agent for the necrosis avid radioiodinated hypericin in rabbits with acute myocardial infarction. Drug Deliv. 2015;22(3):427–435.
   PubMed Web of Science ®Google Scholar
• Liu W, Zhang D, Feng Y, et al. Biodistribution and anti-tumor efficacy of intratumorally injected necrosis-avid theranostic agent radioiodinated hypericin in rodent tumor models. J Drug Target. 2015;23(4):371–379.
   PubMed Web of Science ®Google Scholar
• Shao H, Zhang J, Sun Z, et al. Necrosis targeted radiotherapy with iodine-131-labeled hypericin to improve anticancer efficacy of vascular disrupting treatment in rabbit VX2 tumor models. Oncotarget. 2015;6(16):14247–14259.
   PubMedGoogle Scholar
• Liu X, Feng Y, Jiang C, et al. Radiopharmaceutical evaluation of 131I-protohypericin as a necrosis avid compound. J Drug Target. 2015;23(5):417–426.
   PubMed Web of Science ®Google Scholar
• Liu X, Jiang C, Zhang D, et al. Tumor necrosis targeted radiotherapy of non-small cell lung cancer using radioiodinated protohypericin in a mouse model. Oncotarget. 2015;6(28):26400–26410.
   PubMedGoogle Scholar
• Jiang C, Gao M, Li Y, et al. Exploring diagnostic potentials of radioiodinated sennidin A in rat model of reperfused myocardial infarction. Int J Pharm. 2015;495(1):31–40.
   PubMed Web of Science ®Google Scholar
• Zhang D, Huang D, Ji Y, et al. Experimental evaluation of radioiodinated sennoside B as a necrosis-avid tracer agent. J Drug Target. 2015;23(2):180–190.
   PubMed Web of Science ®Google Scholar
• Zhang D, Jiang C, Yang S, et al. Effects of skeleton structure on necrosis targeting and clearance properties of radioiodinated dianthrones. J Drug Target. 2016;24(6):566–577.
   PubMed Web of Science ®Google Scholar
• Li L, Zhang D, Yang S, et al. Effects of glycosylation on biodistribution and imaging quality of necrotic myocardium of iodine-131-labeled sennidins. Mol Imaging Biol. 2016;18(6):877–886.
   PubMed Web of Science ®Google Scholar
• Wang C, Jin Q, Yang S, et al. Synthesis and evaluation of 131I-skyrin as a necrosis avid agent for potential targeted radionuclide therapy of solid tumors. Mol Pharm. 2016;13(1):180–189.
   PubMed Web of Science ®Google Scholar
• Li J, Zhang J, Yang S, et al. Synthesis and preclinical evaluation of radioiodinated hypericin dicarboxylic acid as a necrosis avid agent in rat models of induced hepatic, muscular, and myocardial necroses. Mol Pharm. 2016;13(1):232–240.
   PubMed Web of Science ®Google Scholar
• Duan X, Yin Z, Jiang C, et al. Radioiodinated hypericin disulfonic acid sodium salts as a DNA-binding probe for early imaging of necrotic myocardium. Eur J Pharm Biopharm. 2017;117:151–159.
   PubMed Web of Science ®Google Scholar
• Wang Q, Yang S, Jiang C, et al. Discovery of radioiodinated monomeric anthraquinones as a novel class of necrosis avid agents for early imaging of necrotic myocardium. Sci Rep. 2016;6(1):21341.
   PubMed Web of Science ®Google Scholar
• Luo Q, Jin Q, Su C, et al. Radiolabeled rhein as small-molecule necrosis avid agents for imaging of necrotic myocardium. Anal Chem. 2017;89(2):1260–1266.
   PubMed Web of Science ®Google Scholar
• Liang J, Luo Q, Zhang D, et al. SPECT imaging of treatment-related tumor necrosis using technetium-99m-labeled rhein. Mol Imaging Biol. 2019;21(4):660–668.
   PubMed Web of Science ®Google Scholar
• Bian L, Gao M, Zhang D, et al. Synthesis and biological evaluation of rhein-based MRI contrast agents for in vivo visualization of necrosis. Anal Chem. 2018;90(22):13249–13256.
   PubMed Web of Science ®Google Scholar
• Wu T, Zhang J, Jin Q, et al. Rhein‐based necrosis‐avid MRI contrast agents for early evaluation of tumor response to microwave ablation therapy. Magn Reson Med. 2019;82(6):2212–2224.
   PubMed Web of Science ®Google Scholar
• Zhang A, Wu T, Bian L, et al. Synthesis and evaluation of Ga-68-labeled rhein for early assessment of treatment-induced tumor necrosis. Mol Imaging Biol. 2019. doi:10.1007/s11307-019-01365-y
   Web of Science ®Google Scholar
• Barnes J, Anderson LA, Phillipson JD. St John’s wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol. 2001;53(5):583–600.
   PubMed Web of Science ®Google Scholar
• Miskovsky P. Hypericin-a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. Curr Drug Targets. 2002;3(1):55–84.
   PubMed Web of Science ®Google Scholar
• Kubin A, Wierrani F, Burner U, et al. Hypericin-the facts about a controversial agent. CPD. 2005;11(2):233–253.
   Web of Science ®Google Scholar
• Karioti A, Bilia AR. Hypericins as potential leads for new therapeutics. IJMS. 2010;11(2):562–594.
   Web of Science ®Google Scholar
• Ni Y, Huyghe D, Verbeke K, et al. First preclinical evaluation of mono-[123I] iodohypericin as a necrosis-avid tracer agent. Eur J Nucl Med Mol Imaging. 2006;33(5):595–601.
   PubMed Web of Science ®Google Scholar
• Van de Putte M, Ni Y, De Witte P. Exploration of the mechanism underlying the tumor necrosis avidity of hypericin. Oncol Rep. 2008;19(4):921–926.
   PubMed Web of Science ®Google Scholar
• Van de Putte M, Wang H, Chen F, et al. Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep. 2008;19(4):927–932.
   PubMed Web of Science ®Google Scholar
• Van de Putte M, Wang H, Chen F, et al. Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. Acad Radiol. 2008;15(1):107–113.
   PubMed Web of Science ®Google Scholar
• Fonge H, Vunckx K, Wang H, et al. Non-invasive detection and quantification of acute myocardial infarction in rabbits using mono-[123I]iodohypericin microSPECT. Eur Heart J. 2007;29(2):260–269.
   PubMed Web of Science ®Google Scholar
• Feng Y, Cona MM, Vunckx K, et al. Detection and quantification of acute reperfused myocardial infarction in rabbits using DISA-SPECT/CT and 3.0 T cardiac MRI. Int J Cardiol. 2013;168(4):4191–4198.
   PubMed Web of Science ®Google Scholar
• Miranda Cona M, Feng Y, Li Y, et al. Comparative study of Iodine-123-labeled-hypericin and Tc-99m-labeled-hexakis [2-methoxyisobutylisonitril] in a rabbit model of myocardial infarction. J Cardiovasc Pharm. 2013;62(3):304–311.
   PubMed Web of Science ®Google Scholar
• Song S, Xiong C, Zhou M, et al. Small-animal PET of tumor damage induced by photothermal ablation with 64Cu-bis-DOTA-hypericin. J Nucl Med. 2011;52(5):792–799.
   PubMed Web of Science ®Google Scholar
• Ishikawa M, Hashimoto Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry. J Med Chem. 2011;54(6):1539–1554.
   PubMed Web of Science ®Google Scholar
• Lewin G, Maciuk A, Moncomble A, et al. Enhancement of the water solubility of flavone glycosides by disruption of molecular planarity of the aglycone moiety. J Nat Prod. 2013;76(1):8–12.
   PubMed Web of Science ®Google Scholar
• Chen Z, Baumeister U, Tschierske C, et al. Effect of core twisting on self-assembly and optical properties of perylene bisimide dyes in solution and columnar liquid crystalline phases. Chem Eur J. 2007;13(2):450–465.
   PubMed Web of Science ®Google Scholar
• Chen Z, Lohr A, Saha-Möller CR, et al. Self-assembled π-stacks of functional dyes in solution: structural and thermodynamic features. Chem Soc Rev. 2009;38(2):564–584.
   PubMed Web of Science ®Google Scholar
• Smith BA, Smith BD. Biomarkers and molecular probes for cell death imaging and targeted therapeutics. Bioconjugate Chem. 2012;23(10):1989–2006.
   PubMed Web of Science ®Google Scholar
• Garanger E, Hilderbrand SA, Blois JT, et al. A DNA-binding Gd chelate for the detection of cell death by MRI. Chem Commun. 2009;(29):4444–4446.
   Web of Science ®Google Scholar
• Dasari M, Lee S, Sy J, et al. Hoechst-IR: an imaging agent that detects necrotic tissue in vivo by binding extracellular DNA. Org Lett. 2010;12(15):3300–3303.
   PubMed Web of Science ®Google Scholar
• Huang S, Chen HH, Yuan H, et al. Molecular MRI of acute necrosis with a novel DNA-binding gadolinium chelate: kinetics of cell death and clearance in infarcted myocardium. Circ Cardiovasc Imaging. 2011;4(6):729–737.
   PubMed Web of Science ®Google Scholar
• Cho H, Alcantara D, Yuan H, et al. Fluorochrome-functionalized nanoparticles for imaging DNA in biological systems. ACS Nano. 2013;7(3):2032–2041.
   PubMed Web of Science ®Google Scholar
• Cho H, Guo Y, Sosnovik DE, et al. Imaging DNA with Fluorochrome Bearing Metals. Inorg Chem. 2013;52(21):12216–12222.
   PubMed Web of Science ®Google Scholar
• Chen HH, Yuan H, Cho H, et al. Theranostic nucleic acid binding nanoprobe exerts anti-inflammatory and cytoprotective effects in ischemic injury. Theranostics. 2017;7(4):814–825.
   PubMed Web of Science ®Google Scholar
• Zhang D, Gao M, Yao N, et al. Preclinical evaluation of radioiodinated Hoechst 33258 for early prediction of tumor response to treatment of vascular-disrupting agents. Contrast Media Mol Imaging. 2018;2018:1–9.
   Google Scholar
• Rescifina A, Zagni C, Varrica MG, et al. Recent advances in small organic molecules as DNA intercalating agents: Synthesis, activity, and modeling. Eur J Med Chem. 2014;74:95–115.
   PubMed Web of Science ®Google Scholar
• Malik EM, Müller CE. Anthraquinones as pharmacological tools and drugs. Med Res Rev. 2016;36(4):705–748.
   PubMed Web of Science ®Google Scholar
• Jin Q, Jiang C, Gao M, et al. Target exploration of rhein as a small-molecule necrosis avid agent by post-treatment click modification. New J Chem. 2019;43(16):6121–6125.
   Web of Science ®Google Scholar
• Zhang S, Sun X, Kong R, et al. Studies on the interaction of apigenin with calf thymus DNA by spectroscopic methods. Spectrochim Acta A Mol Biomol Spectrosc. 2015;136:1666–1670.
   PubMed Web of Science ®Google Scholar
• Ramalho J, Semelka RC, Ramalho M, et al. Gadolinium-based contrast agent accumulation and toxicity: an update. Am J Neuroradiol. 2016;37(7):1192–1198.
   PubMed Web of Science ®Google Scholar
• Kim HK, Lee GH, Chang Y. Gadolinium as an MRI contrast agent. Future Med Chem. 2018;10(6):639–661.
   PubMed Web of Science ®Google Scholar
• Wahsner J, Gale EM, Rodríguez-Rodríguez A, et al. Chemistry of MRI contrast agents: current challenges and new frontiers. Chem Rev. 2019;119(2):957–1057.
   PubMed Web of Science ®Google Scholar
• Gillis EP, Eastman KJ, Hill MD, et al. Applications of fluorine in medicinal chemistry. J Med Chem. 2015;58(21):8315–8359.
   PubMed Web of Science ®Google Scholar
• Van Der Born D, Pees A, Poot AJ, et al. Fluorine-18 labelled building blocks for PET tracer synthesis. Chem Soc Rev. 2017;46(15):4709–4773.
   PubMed Web of Science ®Google Scholar